The main business of Beijing Kangleweishi Biotechnology Co., Ltd. is the research and development of recombinant protein biological products based on structural design. The first series of products currently launched by the company based on structural design are human papillomavirus (HPV) vaccines. The first product in the series of HPV vaccines is the recombinant trivalent human papillomavirus (type 16/18/58) vaccine (E. coli). On January 2, 2018, the company obtained the "Drug Registration Application Acceptance Notice" for the clinical trial of "Recombinant nine-valent human papillomavirus (6/11/16/18/31/33/45/52/58) vaccine (E. coli)" Book".

Headquarters
Rooms 201 and 202, Building A2, Longsheng Industrial Park, No. 7 Rongchang East Street, Beijing Economic and Technological Development Zone
Beijing; Beijing; Postal Code: 100176

Contact Details: Purchase the Beijing Health Guard Biotechnology Inc. (北京康乐卫士生物技术股份有限公司) report to view the information.

Website: http://www.klws.com

Basic Information

Total Employees:

Purchase the Beijing Health Guard Biotechnology Inc. (北京康乐卫士生物技术股份有限公司) report to view the information.

Outstanding Shares:

Purchase the Beijing Health Guard Biotechnology Inc. (北京康乐卫士生物技术股份有限公司) report to view the information.

Financial Auditors:

Purchase the Beijing Health Guard Biotechnology Inc. (北京康乐卫士生物技术股份有限公司) report to view the information.

Incorporation Date:

April 14, 2008

Key Executives